Pharmaceuticals in the Netherlands

Date: June 30, 2017
Pages: 39
Price:
US$ 350.00
License [?]:
Publisher: MarketLine
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: PF5A6557FDCEN
Leaflet:

Download PDF Leaflet

Pharmaceuticals in the Netherlands
Pharmaceuticals in the Netherlands

SUMMARY

Pharmaceuticals in the Netherlands industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

SYNOPSIS

Essential resource for top-line data and analysis covering the Netherlands pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

KEY HIGHLIGHTS
  • The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare. Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors). Any currency conversions used in the production of this report have been calculated at constant 2016 annual average exchange rates.
  • The Dutch pharmaceuticals market had total revenues of $5.0bn in 2016, representing a compound annual rate of change (CARC) of -0.1% between 2012 and 2016.
  • In the Netherlands, ‘preference policy’ sets out a preference system for prescribing a cheaper version of a medicine, provided it has the same efficacy as the brand-name medicine. This is a policy put in place by the insurance providers.
  • The Ministry of Health, Welfare and Sport sets maximum allowable prices for medicines in accordance with the Medicine Prices Act. When buying in drugs, pharmacists may not pay more than the maximum prices. These are set by comparing prices in four reference countries: Belgium, France, Germany and the United Kingdom.
SCOPE
  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in the Netherlands
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in the Netherlands
  • Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the Netherlands pharmaceuticals market with five year forecasts
REASONS TO BUY
  • What was the size of the Netherlands pharmaceuticals market by value in 2016?
  • What will be the size of the Netherlands pharmaceuticals market in 2021?
  • What factors are affecting the strength of competition in the Netherlands pharmaceuticals market?
  • How has the market performed over the last five years?
  • Who are the top competitiors in the Netherlands's pharmaceuticals market?
Executive Summary
Market value
Market value forecast
Geography segmentation
Market share
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market Segmentation
Geography segmentation
Market share
Market Outlook
Market value forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
AstraZeneca PLC
GlaxoSmithKline Plc
Novartis AG
Pfizer Inc.
Macroeconomic Indicators
Country data
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine

LIST OF TABLES

Table 1: Netherlands pharmaceuticals market value: $ billion, 2012–16
Table 2: Netherlands pharmaceuticals market geography segmentation: $ billion, 2016
Table 3: Netherlands pharmaceuticals market share: % share, by value, 2016
Table 4: Netherlands pharmaceuticals market value forecast: $ billion, 2016–21
Table 5: AstraZeneca PLC: key facts
Table 6: AstraZeneca PLC: key financials ($)
Table 7: AstraZeneca PLC: key financial ratios
Table 8: GlaxoSmithKline Plc: key facts
Table 9: GlaxoSmithKline Plc: key financials ($)
Table 10: GlaxoSmithKline Plc: key financials (£)
Table 11: GlaxoSmithKline Plc: key financial ratios
Table 12: Novartis AG: key facts
Table 13: Novartis AG: key financials ($)
Table 14: Novartis AG: key financial ratios
Table 15: Pfizer Inc.: key facts
Table 16: Pfizer Inc.: key financials ($)
Table 17: Pfizer Inc.: key financial ratios
Table 18: Netherlands size of population (million), 2012–16
Table 19: Netherlands gdp (constant 2005 prices, $ billion), 2012–16
Table 20: Netherlands gdp (current prices, $ billion), 2012–16
Table 21: Netherlands inflation, 2012–16
Table 22: Netherlands consumer price index (absolute), 2012–16
Table 23: Netherlands exchange rate, 2012–16

LIST OF FIGURES

Figure 1: Netherlands pharmaceuticals market value: $ billion, 2012–16
Figure 2: Netherlands pharmaceuticals market geography segmentation: % share, by value, 2016
Figure 3: Netherlands pharmaceuticals market share: % share, by value, 2016
Figure 4: Netherlands pharmaceuticals market value forecast: $ billion, 2016–21
Figure 5: Forces driving competition in the pharmaceuticals market in the Netherlands, 2016
Figure 6: Drivers of buyer power in the pharmaceuticals market in the Netherlands, 2016
Figure 7: Drivers of supplier power in the pharmaceuticals market in the Netherlands, 2016
Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the Netherlands, 2016
Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in the Netherlands, 2016
Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in the Netherlands, 2016
Figure 11: AstraZeneca PLC: revenues & profitability
Figure 12: AstraZeneca PLC: assets & liabilities
Figure 13: GlaxoSmithKline Plc: revenues & profitability
Figure 14: GlaxoSmithKline Plc: assets & liabilities
Figure 15: Novartis AG: revenues & profitability
Figure 16: Novartis AG: assets & liabilities
Figure 17: Pfizer Inc.: revenues & profitability
Figure 18: Pfizer Inc.: assets & liabilities

COMPANIES MENTIONED

AstraZeneca PLC
GlaxoSmithKline Plc
Novartis AG
Pfizer Inc.
Skip to top


Ask Your Question

Pharmaceuticals in the Netherlands
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: